Novartis Scales Community Health to 30+ Countries
Novartis has announced a major expansion of its community health programs to address persistent gaps in heart disease and cancer care. The initiative targets populations in low-income, rural, and underserved communities across more than 30 countries by 2030. Currently active in 11 countries, the program will nearly triple its geographic footprint — bringing critical care to millions who lack reliable access to specialist treatment.
This announcement comes at a pivotal moment. Public health progress against chronic diseases has slowed or reversed in many countries, leaving vulnerable populations at greater risk. Novartis is responding with a structured, scalable approach anchored in local partnerships and community-level action.
“We are going further to bring heart disease and cancer care to communities falling through the gaps in health systems,” said Michelle Weese, Chief Corporate Affairs Officer at Novartis. “With millions missing out on potential treatment, there is an urgent need for new, sustainable solutions to improve access to care.”
Three Key Community Health Models
Novartis is deploying three distinct models, each designed for a different setting and population need. Together, these programs address the full spectrum of care — from awareness and early detection to diagnosis and treatment referral.
Inclusive Health Accelerators in the U.S.
The Inclusive Health Accelerator (IHA) model launches this week across five U.S. cities: New York, Los Angeles, Detroit, Houston, and Baltimore. The IHA focuses specifically on closing gaps in breast and prostate cancer care among under-reached populations.
Each city-level program builds partnerships with local community organizations, health authorities, and private businesses. Together, these networks deliver education, free cancer screenings, diagnostic services, and follow-up care referrals. The design is intentionally local — tailoring outreach to the specific demographics and barriers in each city.
Additionally, the IHAs build on existing cardiovascular work. Novartis previously launched the Health Assessments and Rapid Transformation (HEART) program with Meharry Medical College’s School of Global Health to tackle cardiovascular disease in similar communities.
Community Health Initiatives in Emerging Economies
The Community Health Initiative (CHI) model targets low- and middle-income countries. Currently operational in Vietnam, Rwanda, and Bolivia, CHIs work to reach patients beyond conventional commercial channels — connecting people to heart disease and cancer care who would otherwise go undiagnosed.
Novartis plans to expand CHIs to at least seven additional countries by 2030. The model draws heavily on a landmark pilot in rural Vietnam. Over 18 months, that program screened 400,000 people, linked 35,000 to local treatment, and doubled hypertension control rates — from 32% to 76%. Diabetes control rates tripled from 27% to 77%. These results confirm that community-embedded care can deliver measurable, rapid health improvements even in resource-limited settings.
CARDIO4Cities: Data-Driven Urban Heart Health
CARDIO4Cities is a program developed by the Novartis Foundation — an independent non-profit — to improve urban heart health through real-time data, AI, and city-level partnerships. Currently operational in eight countries, including Brazil, the U.S., Belgium, Portugal, Finland, Brunei, Singapore, and Australia, the program aims to expand to 23 countries and 30 major cities by 2030.
The model targets cardiometabolic diseases such as hypertension, proactively reaching residents earlier in the disease course. Implementation studies show three- to six-fold increases in hypertension control, along with associated reductions in stroke and heart attack rates — all within one to two years of deployment.
Why This Expansion Matters Now
Chronic diseases such as heart disease and cancer remain the leading causes of death globally. Furthermore, access to early detection and specialist care is deeply unequal. Rural communities, low-income populations, and marginalized groups consistently face longer delays in diagnosis and worse treatment outcomes.
Progress on non-communicable diseases has stalled in many regions. Research published in The Lancet confirms that cause-specific mortality trends for chronic diseases have worsened in several countries between 2001 and 2019. Without deliberate, community-level intervention, these gaps will persist and likely widen.
Novartis is addressing this by moving care upstream — into communities, not just hospitals. Each of the three models emphasizes prevention, early detection, and local referral pathways. Moreover, all three rely on partnerships rather than Novartis operating alone, making the programs sustainable beyond any single organization’s capacity.
Proven Results Driving Global Ambition
The scale of Novartis’s ambition rests on a credible evidence base. The Vietnam CHI pilot demonstrated that structured, community-based care can double and triple disease control rates within 18 months. CARDIO4Cities has consistently shown hypertension control improvements of three to six times baseline levels, with downstream reductions in cardiovascular events.
These outcomes matter not only for patients but for health system sustainability. Earlier intervention and better disease control reduce hospitalizations, lower treatment costs, and improve long-term productivity in affected communities.
What Comes Next
By 2030, Novartis aims to have all three programs running across more than 30 countries. The five U.S. cities launching this week mark the start of the IHA rollout. CHI expansion into seven additional low- and middle-income countries follows on the Vietnam-Rwanda-Bolivia foundation. CARDIO4Cities will continue adding urban partners across Europe, Asia-Pacific, and the Americas.
Each step involves close collaboration with local governments, NGOs, healthcare providers, and community groups — recognizing that no single actor can solve systemic access gaps alone. Novartis’s approach treats community health not as philanthropy but as a structured, measurable business and social priority.
